Chun-Fung Chan

Title: Innovations of Chun-Fung Chan in Epigenetic Research

Introduction

Chun-Fung Chan is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of epigenetics, particularly in the area of nucleic acid modification. With a total of 2 patents, his work has implications for both cancer therapy and somatic cell nuclear transfer.

Latest Patents

Chan's latest patents include groundbreaking methods for the demethylation of methylated nucleic acid sequences. The first patent describes a molecule that utilizes a cytidine deaminase activity domain and a DNA binding activity domain. This innovative approach is particularly useful in eukaryotic cells for demethylating DNA sequences. The second patent focuses on compositions and methods for epigenetic modification of nucleic acid sequences in vivo, emphasizing the same dual-domain structure for effective application in cancer therapy and somatic cell nuclear transfer.

Career Highlights

Chun-Fung Chan is currently associated with Cellcentric Limited, where he continues to advance research in epigenetic modifications. His work is pivotal in understanding how these modifications can be utilized in therapeutic contexts.

Collaborations

Chan has collaborated with esteemed colleagues such as Wolf Reik and Hugh Morgan, contributing to a rich environment of innovation and research.

Conclusion

Chun-Fung Chan's contributions to epigenetic research through his patents and collaborations highlight his role as a leading inventor in this critical field. His work not only advances scientific understanding but also opens new avenues for therapeutic applications.